By Fineline Cube 
China-based Shandong Kanghua Biotechnology Co., Ltd., a developer of in vitro diagnostic (IVD) reagents, has announced plans to conduct an initial public offering (IPO) of 120 million shares on the Beijing Stock Exchange. This strategic move marks a significant step in the company’s growth and expansion strategy.
Company Overview
Founded in 1996, Kanghua Biotechnology has established itself as a key player in the IVD sector with a comprehensive product line for pathogen detection. The company’s offerings span respiratory tract infections, blood screening, sexually transmitted diseases, gastrointestinal infections, and mother-to-child transmission diseases.
Respiratory Pathogen Detection
In the respiratory tract field, Kanghua Bio provides a robust methodology matrix for POCT (Point-of-Care Testing) real-time diagnosis, high-throughput automated testing, and precise quantitative analysis. The company’s capabilities extend to detecting 13 respiratory pathogens, including Mycoplasma pneumoniae, Chlamydia pneumoniae, respiratory syncytial virus, influenza A virus, and influenza B virus. With over 50 approved respiratory testing products, Kanghua Bio is well-positioned to address the diverse diagnostic needs in the healthcare sector.-Fineline Info & Tech